Literature DB >> 10022169

Acute chest syndrome in the postoperative sickle cell patient.

S J Delatte1, A Hebra, E P Tagge, S Jackson, K Jacques, H B Othersen.   

Abstract

BACKGROUND/
PURPOSE: Acute chest syndrome (ACS), a phenomenon of pulmonary sequestration in sickle cell disease (SCD) patients, is frequently missed in the postoperative SCD child. The constellation of symptoms range from fever and respiratory distress to abdominal discomfort. In its most fulminate state, the syndrome has been reported in some series to carry almost a 25% to 50% mortality rate in the postoperative patient. The incidence in pediatric patients in the era of minimally invasive surgery is unknown.
METHODS: Since December 1995, 63 episodes of ACS have been documented in the nearly 500 SCD children seen at our institution. Six of 63 episodes occurred within 2 weeks after a surgical procedure under general anesthesia. During this period, 59 operations were performed by the pediatric surgery service on SCD patients with an ACS incidence of 10.2%. Careful review of the preoperative, intraoperative, and postoperative management of these patients was performed.
RESULTS: All six received preoperative oxygen saturation monitoring and intravenous fluid (IVF) hydration. One half of these patients required transfusion to achieve a hemoglobin level of greater than 10 mg/dL. Documentation of intraoperative temperature, hypoxia, volume status, and hypercarbia as well as any atypical perioperative events were monitored and reviewed. All patients received postoperative oxygen supplementation and IVF hydration. Onset of ACS ranged from 1 hour to 7 days postoperatively. Only one of six was thought to be of microbial etiology (elevated mycoplasma titers), and all patients received prophylactic antibiotic and aggressive pulmonary therapy. Overall length of hospitalization was increased with an average stay of 6.1 days. There were no postsurgical ACS deaths.
CONCLUSIONS: Despite close attention and avoidance of known risk factors for development of postoperative SCD complications, ACS occurred with an incidence much higher than previously reported in the literature (0.4% v 10.2%). Interestingly, five of six cases were after laparoscopic procedures suggesting that the advantages of laparoscopy, such as reduced postoperative pain, do not extrapolate to decreased incidence of ACS.

Entities:  

Mesh:

Year:  1999        PMID: 10022169     DOI: 10.1016/s0022-3468(99)90254-3

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  6 in total

Review 1.  Antibiotics for treating acute chest syndrome in people with sickle cell disease.

Authors:  Arturo J Martí-Carvajal; Lucieni O Conterno; Jennifer M Knight-Madden
Journal:  Cochrane Database Syst Rev       Date:  2015-03-06

2.  Low-impact laparoscopic cholecystectomy is associated with decreased postoperative morbidity in patients with sickle cell disease.

Authors:  Nicola de'Angelis; Solafah Abdalla; Maria Clotilde Carra; Vincenzo Lizzi; Aleix Martínez-Pérez; Anoosha Habibi; Pablo Bartolucci; Frédéric Galactéros; Alexis Laurent; Francesco Brunetti
Journal:  Surg Endosc       Date:  2017-11-02       Impact factor: 4.584

Review 3.  The spleen in the sickling disorders: an update.

Authors:  Rana Khatib; Raja Rabah; Sharada A Sarnaik
Journal:  Pediatr Radiol       Date:  2008-11-11

4.  Perioperative management in children with sickle cell disease undergoing laparoscopic surgery.

Authors:  Claudio Sandoval; Gustavo Stringel; M Fevzi Ozkaynak; Oya Tugal; Somasundaram Jayabose
Journal:  JSLS       Date:  2002 Jan-Mar       Impact factor: 2.172

5.  Antibiotics for treating acute chest syndrome in people with sickle cell disease.

Authors:  Arturo J Martí-Carvajal; Lucieni O Conterno; Jennifer M Knight-Madden
Journal:  Cochrane Database Syst Rev       Date:  2019-09-18

Review 6.  Perioperative Management of Sickle Cell Disease.

Authors:  Kwame Ofori Adjepong; Folashade Otegbeye; Yaw Amoateng Adjepong
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-05-01       Impact factor: 2.576

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.